ORYN 1053
Alternative Names: ORYN-1053Latest Information Update: 08 Sep 2023
At a glance
- Originator Oryn Therapeutics
- Class Antineoplastics; Macrocyclic compounds; Peptides
- Mechanism of Action Immunomodulators; Myeloid-derived suppressor cell inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 06 Sep 2023 Oryn Therapeutics has patent protection for OrynotidesTM(Oryn therapeutics website, September 2023)
- 06 Sep 2023 Preclinical trials in Cancer in USA (Parenteral) (Oryn Therapeutics pipeline, September 2023)
- 06 Sep 2023 Pharmacodynamics and adverse events data from preclinical studies in Cancer released by Oryn Therapeutics (Oryn Therpeutics website, September 2023)